FDA clears Wandercraft’s Eve self-balancing exoskeleton for personal use in adults with spinal cord injury
- nuaxia
- 1일 전
- 2분 분량
The clearance extends Wandercraft’s self-balancing exoskeleton technology beyond supervised rehabilitation, allowing eligible adults with spinal cord injuries to use Eve for hands-free upright mobility and daily activities with a trained companion.
The US Food and Drug Administration (FDA) has cleared Wandercraft’s Eve personal exoskeleton for eligible adults with spinal cord injuries at any level who can operate the device’s remote, enabling hands-free walking and activities of daily living on specified level surfaces under the supervision of a trained companion.
The clearance creates a personal-use pathway for Wandercraft’s self-balancing technology outside rehabilitation institutions, with a US commercial launch planned for 17 September 2026.
Field | Content |
Alert Type | Drug Approval |
Drug Name | Eve personal exoskeleton |
Indication | Personal-use powered exoskeleton for eligible adults with spinal cord injuries at any level who can operate Eve’s remote, supporting walking and activities of daily living on level indoor surfaces and immediately adjacent level outdoor areas under the supervision of a specially trained companion. (MassDevice) |
Therapy Area(s) | Neurology; Spinal cord injury; Rehabilitation and mobility |
Geography | United States (FDA) |
What Happened | Wandercraft announced FDA clearance of Eve, its personal self-balancing exoskeleton, on 12 August 2026. Eligible adults with spinal cord injuries at any level who can operate the remote can use the device to walk and perform activities of daily living hands-free on specified level surfaces under supervision of a trained companion. Before use, patients require assessment by a licensed healthcare practitioner, individual device fitting and training alongside their companion. Unlike Wandercraft’s Atalante X, which is designed for use in rehabilitation institutions, Eve provides a pathway for personal use outside the rehabilitation setting. (MassDevice) |
Why It Matters | Existing FDA-cleared personal exoskeletons such as ReWalk and Indego rely on crutches for balance and propulsion, while Eve uses self-balancing technology to enable hands-free upright mobility. For eligible people with spinal cord injuries, the clearance therefore introduces a different personal mobility option designed around standing, walking and performing everyday activities without requiring crutches for balance, although use still requires a trained companion and is restricted to specified surfaces. (MassDevice) |
Supporting Context | FDA clearance was supported by a three-site clinical study involving people with spinal cord injuries and their companions. Participants underwent structured training followed by functional, usability and task-based assessments, with the programme evaluating whether users and companions could learn to operate Eve and complete activities relevant to personal use. (MassDevice) |
Key Takeaway | FDA clearance moves Wandercraft’s self-balancing exoskeleton technology from rehabilitation-centre use towards personal mobility for eligible adults living with spinal cord injury. |
What to Watch | Wandercraft plans to launch Eve commercially in the US on 17 September 2026 and anticipates potential Medicare reimbursement eligibility within 60–90 days; reimbursement is not yet confirmed. The company has also established evaluation, training and distribution partnerships ahead of launch. (MassDevice) |
Primary Source | Wandercraft FDA clearance announcement; US Food and Drug Administration |
Relevant Date | 12 August 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
댓글